Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2011
Event: Entry into a Material Definitive Agreement with Amgen USA Inc.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses on a new contractual agreement and forward-looking guidance.
Material Changes and Agreements
- New Agreement: On November 15, 2011, DaVita entered into a seven-year Sourcing and Supply Agreement with Amgen USA Inc.
- Scope: The agreement covers the purchase of Epoetin alfa (Epogen) to meet at least 90% of DaVita's requirements for erythropoiesis stimulating agents.
- Term: Effective January 1, 2012, through December 31, 2018.
- Replacement: This agreement replaces the prior Dialysis Organization Agreement which expired on December 31, 2011.
- Pricing Structure: Includes discount pricing and rebates. The filing notes that the total rebate opportunity in the initial years is less than what was provided under the expiring agreement.
- Conditions: Rebates are subject to conditions including future pricing levels and data submission. The agreement allows for termination for breach and renegotiation in the event of regulatory changes.
Guidance and Management Commentary
- 2012 Operating Income Guidance: Management reaffirmed its operating income guidance range for 2012 at $1,200 million to $1,300 million.
- Regulation FD Disclosure: The guidance and agreement details are furnished under Regulation FD and are not deemed "filed" for Section 18 liability purposes under the Exchange Act.
Investor Verification Checklist
- Verify the specific rebate calculation formulas and conditions in the full text of the Sourcing and Supply Agreement (expected as an exhibit to the 2011 Form 10-K).
- Assess the financial impact of the reduced rebate opportunity in the initial years compared to the expiring agreement.
- Monitor future pricing levels of Epogen by Amgen USA as a variable affecting rebate eligibility.
- Confirm the execution of the agreement's start date of January 1, 2012.